A$75 million committed for new medicine subsidies in Australia

1 April 2015

The Australian government has announced a further A$75 million ($58 million) commitment to list three new drugs on the Pharmaceutical Benefits Scheme (PBS).

From April 1, 2015, the following listings will be added to the PBS:

alemtuzumab (trade name Lemtrada), from French pharma major Sanofi (Euronext: SAN), for the treatment of relapsing-remitting multiple sclerosis (RRMS);
everolimus (Afinitor), from Swiss giant Novartis (NOVN: VX) for the treatment of metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumor (pNET); and
leuprorelin (Lucrin), from Japan’s Takeda Pharmaceutical (TYO: 4502), for the treatment of central precocious puberty (CPP).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK